Future studies should focus on developing selective TGR5 modulators, evaluating long-term safety profiles, and translating these findings into clinical applications to determine whether TGR5-based therapies can effectively combat metabolic disorders in humans. Here, GPBAR1 is linked to Other metabolic disease.